VentiRx Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- VentiRx Pharmaceuticals's estimated annual revenue is currently $1.7M per year.
- VentiRx Pharmaceuticals's estimated revenue per employee is $155,000
Employee Data
- VentiRx Pharmaceuticals has 11 Employees.
- VentiRx Pharmaceuticals grew their employee count by -15% last year.
VentiRx Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $8.5M | 55 | -21% | N/A | N/A |
#2 | $0.2M | 1 | 0% | N/A | N/A |
#3 | $8.5M | 55 | -29% | N/A | N/A |
#4 | $108.5M | 500 | 2% | N/A | N/A |
#5 | $0.8M | 5 | 0% | N/A | N/A |
#6 | $0.6M | 4 | 0% | N/A | N/A |
#7 | $14.7M | 68 | -23% | $206.4M | N/A |
#8 | $492.2M | 1503 | -15% | $568M | N/A |
#9 | $1.1M | 7 | -42% | N/A | N/A |
#10 | $4.5M | 29 | 0% | N/A | N/A |
What Is VentiRx Pharmaceuticals?
VentiRx is a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like Receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory and inflammatory diseases. VentiRx has a broad clinical pipeline. The lead clinical oncology asset, VTX-2337, is a small molecule TLR8 agonist, currently in multiple clinical trials in combination with chemotherapies and monoclonal antibodies. The company has entered into a worldwide strategic collaboration with Celgene Corporation for this program.
keywords:N/A
N/A
Total Funding
11
Number of Employees
$1.7M
Revenue (est)
-15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Summit
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 13 | 0% | N/A |
#2 | $2M | 16 | 14% | N/A |
#3 | $1.4M | 16 | -11% | N/A |
#4 | $2.5M | 18 | 0% | N/A |
#5 | $3.5M | 18 | -10% | N/A |